PAVmed FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]
PAVmed Inc. (PAVM)
US:NASDAQ Investor Relations:
ir.pavm.com
Company Research
Source: Seeking Alpha
SummaryPAVmed's carpal tunnel syndrome device CarpX is approved.Prothena's Parkinson's study flops, taking the stock down.Mallinckrodt's kidney failure drug application is accepted by the FDA.PAVmed Receives FDA Approval for Carpal Tunnel DevicePAVmed (PAVMThe CarpX clinical safety study involved twenty patients who underwent minimally invasive carpal tunnel release and achieved the pre-specified effectiveness endpoint of endoscopic confirmation of complete division of the transverse carpal ligament. Post operative follow up rate at two week and 90 days were 100 percent and 95 percent, respectively. All the patients who completed follow up also met primary safety endpoint of no serious device related adverse events.CarpX is designed to treat carpal tunnel syndrome in a reduced recovery time. It works by mimicking the anatomic results of invasive carpal tunnel surgery. Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive OfficersaidCarpX procedure involves 5 to 10 mm keyhole incis
Show less
Read more
Impact Snapshot
Event Time:
PAVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PAVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PAVM alerts
High impacting PAVmed Inc. news events
Weekly update
A roundup of the hottest topics
PAVM
News
- PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024PR Newswire
- Veris teams up with Ohio University for cancer digital health pilot [Yahoo! Finance]Yahoo! Finance
- PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute [Yahoo! Finance]Yahoo! Finance
- PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstitutePR Newswire
- Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month [Yahoo! Finance]Yahoo! Finance
PAVM
Sec Filings
- 5/1/24 - Form 8-K
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form ARS
- PAVM's page on the SEC website